327 related articles for article (PubMed ID: 15781657)
1. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Sharma A; Trivedi NR; Zimmerman MA; Tuveson DA; Smith CD; Robertson GP
Cancer Res; 2005 Mar; 65(6):2412-21. PubMed ID: 15781657
[TBL] [Abstract][Full Text] [Related]
2. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
Hingorani SR; Jacobetz MA; Robertson GP; Herlyn M; Tuveson DA
Cancer Res; 2003 Sep; 63(17):5198-202. PubMed ID: 14500344
[TBL] [Abstract][Full Text] [Related]
3. SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.
Tsavachidou D; Coleman ML; Athanasiadis G; Li S; Licht JD; Olson MF; Weber BL
Cancer Res; 2004 Aug; 64(16):5556-9. PubMed ID: 15313890
[TBL] [Abstract][Full Text] [Related]
4. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
[TBL] [Abstract][Full Text] [Related]
5. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Karreth FA; DeNicola GM; Winter SP; Tuveson DA
Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
7. Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF.
Christensen C; Guldberg P
Oncogene; 2005 Sep; 24(41):6292-302. PubMed ID: 16007203
[TBL] [Abstract][Full Text] [Related]
8. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
9. The oncogenic B-raf V599E mutation occurs more frequently in melanomas at sun-protected body sites.
Deichmann M; Krahl D; Thome M; Wüst K; Hassanzadeh J; Helmke B
Int J Oncol; 2006 Jul; 29(1):139-45. PubMed ID: 16773193
[TBL] [Abstract][Full Text] [Related]
10. Detection of B-RAF and N-RAS mutations in human melanoma.
Goydos JS; Mann B; Kim HJ; Gabriel EM; Alsina J; Germino FJ; Shih W; Gorski DH
J Am Coll Surg; 2005 Mar; 200(3):362-70. PubMed ID: 15737846
[TBL] [Abstract][Full Text] [Related]
11. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs.
Yeh AH; Bohula EA; Macaulay VM
Oncogene; 2006 Oct; 25(50):6574-81. PubMed ID: 16715137
[TBL] [Abstract][Full Text] [Related]
12. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
13. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
Ikenoue T; Hikiba Y; Kanai F; Tanaka Y; Imamura J; Imamura T; Ohta M; Ijichi H; Tateishi K; Kawakami T; Aragaki J; Matsumura M; Kawabe T; Omata M
Cancer Res; 2003 Dec; 63(23):8132-7. PubMed ID: 14678966
[TBL] [Abstract][Full Text] [Related]
14. Protein kinase D3 sensitizes RAF inhibitor RAF265 in melanoma cells by preventing reactivation of MAPK signaling.
Chen J; Shen Q; Labow M; Gaither LA
Cancer Res; 2011 Jun; 71(12):4280-91. PubMed ID: 21527556
[TBL] [Abstract][Full Text] [Related]
15. B-Raf(V600E) signaling deregulates the mitotic spindle checkpoint through stabilizing Mps1 levels in melanoma cells.
Cui Y; Guadagno TM
Oncogene; 2008 May; 27(22):3122-33. PubMed ID: 18071315
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
Kim YK; Ahn SK; Lee M
Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Takezawa K; Okamoto I; Yonesaka K; Hatashita E; Yamada Y; Fukuoka M; Nakagawa K
Cancer Res; 2009 Aug; 69(16):6515-21. PubMed ID: 19638574
[TBL] [Abstract][Full Text] [Related]
19. Lack of BRAF mutations in uveal melanoma.
Rimoldi D; Salvi S; Liénard D; Lejeune FJ; Speiser D; Zografos L; Cerottini JC
Cancer Res; 2003 Sep; 63(18):5712-5. PubMed ID: 14522889
[TBL] [Abstract][Full Text] [Related]
20. B-RAF: A contributor to the melanoma phenotype.
Heath EM; Kaufman KL; Christopherson RI
Int J Biochem Cell Biol; 2011 Jan; 43(1):29-32. PubMed ID: 20883818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]